| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Pediatrix Medical Group, Inc.$25.88
+1.77 (+7.34%)
D 34Pipeline Score Tools & Services · Commercial
Market Cap
1.78 B
EPS
1.96
P/E Ratio
11.07 $
Value Trade
14.81 M
SEC Financials
Q1 2026Dilution Risk
Revenue
476.20 M
Operating CF
-129.85 M
Total Assets
2.07 B
Total Liabilities
1.19 B
Equity
878.58 M
D/E Ratio
12,345
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
328.97 M
Monthly Burn
43.28 M
Runway
5.4 mo
Burn Trend
SEC Filing
May 5, 2026
Overview
Volume
1.62 M
52 Week Range
11.84 - 24.99
% held by Insiders
1.6 %
% held by Institutions
103.11 %
Enterprise Value
1.92 B
Total Shares
82.12 M
Short %
4.71 %
Float Shares
80.07 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
D34
Pipeline Score $80M
Pipeline ValueValuation Signal
4
Drugs Scored0.0x
rNPV / MCap Top 44%
Micro Cap (rank 512 of 912)
Percentile RankPediatrix Medical Group, Inc. faces pipeline headwinds (34/100), with $2.0B risk-adjusted pipeline value, led by Parenteral Nutrition in Malnutrition (Phase 3), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Parenteral Nutrition Small molecule | Malnutrition | Phase 3 | NCT00120926 | 53% | $1.6B | COMPLETED | 150 | - | - | Jun 1, 2006 | - | Sep 28, 2006 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in MD
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
MD Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-11-20 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-11-20 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-11-20 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-MD
Jul 15, 2026▲ +7.3%on this news
Pediatrix Medical Group Provides Second Quarter Update
Pediatrix Medical Group, Inc. has provided an update on its second quarter 2026 business trends, confirming that its payor mix has remained stable and unchanged compared to recent historical trends. This announcement comes in light of recent reports from other healthcare market participants regarding shifting utilization and reimbursement trends. The company's position as a leading provider of physician services remains intact.
Read more →-MD
May 5, 2026▼ -7.1%on this news
FOR MORE INFORMATION: Kasandra H. Rossi Executive Vice President, Chief Financial Officer & Treasurer 954-692-7163 kasandra.rossi@pediatrix.com FOR IMMEDIATE RELEASE Pediatrix Medical Group Reports First Quarter Results
Pediatrix Medical Group, Inc. reported its first-quarter earnings for 2026, showing a net revenue of $476 million and a net income of $30 million. The company experienced growth in adjusted earnings per share and EBITDA, exceeding prior expectations. Despite these positive results, the organization faced declines in patient volume and an increase in operating expenses. The company has reaffirmed its annual Adjusted EBITDA guidance for 2026, positioning itself for future opportunities.
Read more →-MD
Feb 23, 2026Pediatrix Medical Group Announces 47th Annual NEO: The Conference for Neonatology
Pediatrix Medical Group will host the 47th annual NEO: The Conference for Neonatology from February 25-27 in Las Vegas. The conference aims to bring together leading experts to discuss advancements and challenges in neonatal-perinatal medicine. With a focus on improving outcomes for newborns, the event will feature interactive sessions and the induction of Dr. Waldemar Carlo into the Legends of Neonatology Hall of Fame.
Read more →-MD
Feb 19, 2026▼ -12.2%on this newsshared move
FOR MORE INFORMATION: Kasandra H. Rossi Executive Vice President, Chief Financial Officer & Treasurer 954-692-7163 kasandra.rossi@pediatrix.com FOR IMMEDIATE RELEASE Pediatrix Medical Group Reports Fourth Quarter Results
Pediatrix Medical Group reported its fourth quarter results for 2025, highlighting earnings of $0.40 per share and an adjusted EBITDA of $66 million. The company experienced a revenue decrease from $502 million to $494 million compared to the previous year, although same-unit revenue grew by 4.0%. The financial results reflect an overall solid performance despite some headwinds in the healthcare industry. The company anticipates a promising 2026 with an expected adjusted EBITDA range of $280 million to $300 million.
Read more →-MD
Nov 3, 2025▲ +24.2%on this news
FOR MORE INFORMATION: Kasandra H. Rossi Executive Vice President, Chief Financial Officer & Treasurer 954-692-7163 kasandra.rossi@pediatrix.com FOR IMMEDIATE RELEASE Pediatrix Medical Group Reports Third Quarter Results
Pediatrix Medical Group reported its third quarter results, revealing earnings of $0.84 per share and a non-GAAP Adjusted EPS of $0.67. The company exceeded its expectations, attributing strong performance to improved collection activity and a favorable payor mix. Despite a decrease in net revenue year-over-year, the outlook for full year 2025 Adjusted EBITDA has been raised to between $270 million and $290 million. However, challenges remain as the company navigates a changing healthcare landscape.
Read more →-MD
Aug 18, 2025FOR MORE INFORMATION: Kasandra H. Rossi Executive Vice President, Chief Financial Officer & Treasurer 954-692-7163 kasandra.rossi@pediatrix.com FOR IMMEDIATE RELEASE Pediatrix Medical Group Announces $250 Million Share R
Pediatrix Medical Group, Inc. has announced a $250 million share repurchase program authorized by its Board of Directors. The initiative stems from the company's strong cash flow and low debt levels, suggesting a solid financial foundation. Management intends to use the program strategically while balancing other investment opportunities. However, the actual execution of the repurchases is contingent on market conditions and can be halted at any moment, introducing an element of uncertainty.
Read more →-MD
Aug 5, 2025▲ +5%on this news· ran to +17% by day 1
FOR MORE INFORMATION: Kasandra H. Rossi Executive Vice President, Chief Financial Officer & Treasurer 954-692-7163 kasandra.rossi@pediatrix.com FOR IMMEDIATE RELEASE Pediatrix Medical Group Reports Second Quarter Results
Pediatrix Medical Group reported strong second quarter results with earnings of $0.46 per share and raised its full-year Adjusted EBITDA outlook to between $245 and $255 million. Despite a decrease in net revenue compared to the previous year, the company experienced growth in same-unit net revenue and reported a net income improvement. The performance is attributed to stable payor mix and strong patient volumes in neonatology services. However, Pediatrix remains cautious regarding future market conditions.
Read more →-MD
Jul 1, 2025FOR MORE INFORMATION: Kasandra Rossi Executive Vice President, Chief Financial Officer and Treasurer 954-692-7163 kasandra.rossi@pediatrix.com FOR IMMEDIATE RELEASE Pediatrix Board Appoints Kurt D. Newman, M.D. as Indepe
Pediatrix Medical Group, Inc. has appointed Kurt D. Newman, M.D. as an independent director effective July 1, 2025. Dr. Newman, a former President and CEO of Children's National Hospital, brings extensive experience in pediatric healthcare and innovation. His commitment to patient-centered care and mental health advocacy highlights the alignment with Pediatrix's mission. The board expresses confidence that Dr. Newman's insights will enhance the company’s strategic direction in upcoming challenges.
Read more →-MD
May 6, 2025▲ +11.8%on this news
FOR MORE INFORMATION: Kasandra H. Rossi Executive Vice President, Chief Financial Officer & Treasurer 954-692-7163 kasandra.rossi@pediatrix.com FOR IMMEDIATE RELEASE Pediatrix Medical Group Reports First Quarter Results
Pediatrix Medical Group reported a strong first quarter performance for 2025, with earnings of $0.24 per share and raising its Adjusted EBITDA outlook for the year to a range of $220 million to $240 million. Despite experiencing a decline in net revenue compared to the previous year, the company saw growth in same-unit revenue and improved payor mix. The results reflect effective cost management and the impact of restructuring initiatives. However, Pediatrix remains cautious due to uncertainties in the healthcare sector.
Read more →-MD
Feb 20, 2025▲ +22.1%on this news
FOR MORE INFORMATION: Charles Lynch Senior Vice President, Finance and Strategy 954-384-0175, x 5692 charles.lynch@pediatrix.com FOR IMMEDIATE RELEASE Pediatrix Medical Group Reports Fourth Quarter Results
Pediatrix Medical Group announced its financial results for the fourth quarter of 2024, reporting earnings of $0.36 per share and an adjusted EPS of $0.51. The company's net revenue rose to $502 million alongside a net income of $30 million. Key metrics showed an 8.7% growth in same-unit revenue despite some impacts from practice dispositions. The company also noted a strong financial position with an increase in cash reserves and an expected positive outlook for 2025 Adjusted EBITDA.
Read more →-MD
Jan 13, 2025▲ +7%on this news
FOR MORE INFORMATION: Charles Lynch Senior Vice President, Finance and Strategy 954-384-0175, x 5692 charles.lynch@pediatrix.com FOR IMMEDIATE RELEASE Pediatrix Announces Strategic Initiatives For Enhanced Shareholder Va
Pediatrix Medical Group, Inc. has announced a leadership transition with Executive Chair Mark S. Ordan returning as Chief Executive Officer. This change aims to enhance shareholder value and strengthen the company's focus on hospital relationships and clinical excellence. The company has initiated several strategic initiatives, including a shift to a hybrid revenue cycle management model and divesting certain clinics. Pediatrix expects to achieve an adjusted EBITDA at the higher end of its 2024 outlook, with upcoming earnings results to be released in February 2025.
Read more →-MD
Nov 1, 2024▲ +23.5%on this news
FOR MORE INFORMATION: Charles Lynch Senior Vice President, Finance and Strategy 954-384-0175, x 5692 charles.lynch@pediatrix.com FOR IMMEDIATE RELEASE Pediatrix Medical Group Reports Third Quarter Results
Pediatrix Medical Group has reported its third quarter results for 2024, revealing a modest exceedance of expectations with earnings of $0.23 per share and an Adjusted EPS of $0.44. The company reported net revenue of $511 million, which reflects a 5.2% increase in same-unit revenue. However, despite this positive growth, net income has decreased compared to last year. The firm has also incurred significant transformational expenses as part of its hybrid revenue cycle management transition.
Read more →-MD
Aug 6, 2024▲ +17.7%on this news· ran to +31% by day 3
FOR MORE INFORMATION: Charles Lynch Senior Vice President, Finance and Strategy 954-384-0175, x 5692 charles.lynch@pediatrix.com FOR IMMEDIATE RELEASE Pediatrix Medical Group Reports Second Quarter Results
Pediatrix Medical Group reported a net loss of $153 million for the second quarter of 2024, significantly down from a net income of $28.3 million in the same period last year. Though net revenue increased slightly to $504 million, the company faced substantial operational challenges, including a large non-cash impairment charge. The management confirmed their ongoing portfolio management plans, which include exiting several office-based practices, aimed at improving financial performance by year’s end. Leadership transitions were also announced as part of the restructuring efforts.
Read more →-MD
May 30, 2024Pediatrix Medical Group, Inc. (NYSE:MD) Supplemental Disclosure
Pediatrix Medical Group, Inc. (MD) has provided updates regarding its operational focus and portfolio optimization strategy, highlighting a projected Adjusted EBITDA range of $200 million to $220 million for 2024. The company is set to exit several office-based practices as part of its optimization plans, which it aims to complete by the end of the year. While the changes are expected to enhance operational efficiency, there are inherent risks associated with transitioning to new management processes and external factors affecting performance.
Read more →-MD
May 7, 2024FOR MORE INFORMATION: Charles Lynch Senior Vice President, Finance and Strategy 954-384-0175, x 5692 charles.lynch@pediatrix.com FOR IMMEDIATE RELEASE Pediatrix Medical Group Reports First Quarter Results
Pediatrix Medical Group, Inc. announced its first-quarter results for 2024, reporting a net revenue of $495 million. Although the company experienced a decline in net income and adjusted earnings per share compared to the previous year, growth in same-unit revenue suggests a positive trend. The company emphasized its focus on operating efficiency and margin stabilization as key priorities moving forward. However, they also reported increased general and administrative expenses and substantial cash use for continuing operations.
Read more →-MD
Feb 20, 2024▼ -8.9%on this news
FOR MORE INFORMATION: Charles Lynch Senior Vice President, Finance and Strategy 954-384-0175, x 5692 charles.lynch@pediatrix.com
Pediatrix Medical Group, Inc. reported a loss from continuing operations of $1.50 per share for the fourth quarter of 2023, reflecting a significant overall downfall with net revenue falling to $496 million. The latest financial results showed a decrease in same-unit revenue, impacted by patient volume and reimbursement factors. Despite implementing a hybrid revenue-cycle management structure and anticipating improved cash flow, the company struggled with a substantial loss and impairment charges. Moving forward, Pediatrix expect fourth quarter Adjusted EBITDA to range between $200 million and $220 million for 2024.
Read more →-MD
May 4, 2023▼ -6.9%on this news
FOR MORE INFORMATION: Charles Lynch Senior Vice President, Finance and Strategy 954-384-0175, x 5692 charles.lynch@pediatrix.com FOR IMMEDIATE RELEASE Pediatrix Board Appoints Sylvia Young as Independent Director
Pediatrix Medical Group has appointed Sylvia Young as an independent director, effective May 12, 2023. Young brings over three decades of experience in hospital administration, most recently as President and CEO of the HCA Continental Division. The board expressed that her deep knowledge of the healthcare sector, especially in women's and children's services, will add significant value to Pediatrix. Young has a commendable track record and was recognized among the top women in healthcare in 2022.
Read more →-MD
Dec 15, 2022FOR MORE INFORMATION: Charles Lynch Senior Vice President, Finance and Strategy 954-384-0175, x 5692 charles.lynch@pediatrix.com FOR IMMEDIATE RELEASE Pediatrix Announces Leadership Transitions James D. Swift, M.D., Appo
FOR MORE INFORMATION: Senior Vice President, Finance and Strategy 954-384-0175, x 5692 charles.lynch@pediatrix.com Pediatrix Announces Leadership Transitions James D. Swift, M.D., Appointed Chief Executive Officer; Mark S. Ordan Appointed Executive Chair of Board of Director
Read more →-MD
Jun 21, 2022FOR MORE INFORMATION: Charles Lynch Senior Vice President, Finance and Strategy 954-384-0175, x 5692 charles_lynch@mednax.com FOR IMMEDIATE RELEASE Mednax To Change Name to Pediatrix Medical Group, Inc. Effective
FOR MORE INFORMATION: Senior Vice President, Finance and Strategy 954-384-0175, x 5692 charles_lynch@mednax.com Mednax To Change Name to Pediatrix Medical Group, Inc. Effective July 1, 2022 FORT LAUDERDALE, Fla., June 21, 2022 - Mednax, Inc. (NYSE: MD) today announced that i
Read more →-MD
Apr 28, 2022▼ -8.9%on this news
FOR MORE INFORMATION: Charles Lynch Senior Vice President, Finance and Strategy 954-384-0175, x 5692 charles_lynch@mednax.com FOR IMMEDIATE RELEASE Mednax Reports First Quarter Results
FOR MORE INFORMATION: Senior Vice President, Finance and Strategy 954-384-0175, x 5692 charles_lynch@mednax.com Mednax Reports First Quarter Results FORT LAUDERDALE, Fla., April 28, 2022 - Mednax, Inc. (NYSE: MD), whose affiliated practices operate as Pediatrix Medical Group
Read more →-MD
Feb 17, 2022▼ -6.1%on this news
FOR MORE INFORMATION: Charles Lynch Senior Vice President, Finance and Strategy 954-384-0175, x 5692 charles_lynch@mednax.com FOR IMMEDIATE RELEASE Mednax Reports Fourth Quarter Results
FOR MORE INFORMATION: Senior Vice President, Finance and Strategy 954-384-0175, x 5692 charles_lynch@mednax.com Mednax Reports Fourth Quarter Results FORT LAUDERDALE, Fla., February 17, 2022 - Mednax, Inc. (NYSE: MD), and its affiliated practices operating as Pediatrix Medic
Read more →-MD
Feb 14, 2022FOR MORE INFORMATION: Charles Lynch Senior Vice President, Finance and Strategy 954-384-0175 ext. 5692 charles_lynch@mednax.com FOR IMMEDIATE RELEASE Mednax Announces Closing of $1.1 Billion in Financing Transactions Red
FOR MORE INFORMATION: Senior Vice President, Finance and Strategy 954-384-0175 ext. 5692 charles_lynch@mednax.com Mednax Announces Closing of $1.1 Billion in Financing Transactions Redeems 6.25% Senior Notes Due 2027 FORT LAUDERDALE, Fla. February 14, 2022 -- Mednax, Inc. (
Read more →-MD
Oct 28, 2021FOR MORE INFORMATION: Charles Lynch Senior Vice President, Finance and Strategy 954-384-0175, x 5692 charles_lynch@mednax.com FOR IMMEDIATE RELEASE Mednax Reports Third Quarter Results
FOR MORE INFORMATION: Senior Vice President, Finance and Strategy 954-384-0175, x 5692 charles_lynch@mednax.com Mednax Reports Third Quarter Results FORT LAUDERDALE, Fla., October 28, 2021 - Mednax, Inc. (NYSE: MD), the national medical group specializing in prenatal, neonat
Read more →-MD
Aug 6, 2021▲ +9.3%on this news
FOR MORE INFORMATION: Charles Lynch Senior Vice President, Finance and Strategy 954-384-0175, x 5692 charles_lynch@mednax.com FOR IMMEDIATE RELEASE Mednax Reports Second Quarter Results
FOR MORE INFORMATION: Senior Vice President, Finance and Strategy 954-384-0175, x 5692 charles_lynch@mednax.com Mednax Reports Second Quarter Results FORT LAUDERDALE, Fla., August 6, 2021 - Mednax, Inc. (NYSE: MD), the national medical group specializing in prenatal, neonata
Read more →-MD
Dec 15, 2020UNAUDITED PRO FORMA CONSOLIDATED FINANCIAL INFORMATION Overview On
UNAUDITED PRO FORMA CONSOLIDATED FINANCIAL INFORMATION On December 15, 2020, Mednax, Inc., a Florida corporation ( the Company ), pursuant to the previously disclosed Securities Purchase Agreement, dated as of September 9, 2020, by and between Mednax Services, Inc., a Florida c
Read more →-MD
Nov 6, 2020FOR MORE INFORMATION: Charles Lynch Senior Vice President, Finance and Strategy 954-384-0175, x 5692 charles_lynch@mednax.com FOR IMMEDIATE RELEASE MEDNAX Reports Third Quarter Results
FOR MORE INFORMATION: Senior Vice President, Finance and Strategy charles_lynch@mednax.com Third Quarter Results FORT LAUDERDALE, Fla., November 6, 2020 MEDNAX, Inc. (NYSE: MD), the national health solutions partner specializing in prenatal, neonatal, and pediatric services
Read more →-MD
Sep 10, 2020FOR MORE INFORMATION: Charles Lynch Senior Vice President, Finance and Strategy 954-384-0175 ext. 5692 charles_lynch@mednax.com FOR IMMEDIATE RELEASE MEDNAX Announces Agreement to Sell MEDNAX Radiology Solutions to Radio
FOR MORE INFORMATION: Senior Vice President, Finance and Strategy 954-384-0175 ext. 5692 charles_lynch@mednax.com MEDNAX Announces Agreement to Sell MEDNAX Radiology Solutions to Radiology Partners Transaction Enables Singular Focus on Pediatrix and Obstetrix Medical Groups
Read more →-MD
Aug 25, 2020FOR MORE INFORMATION: Charles Lynch Senior Vice President, Finance and Strategy 954-384-0175 ext. 5692 charles_lynch@mednax.com FOR IMMEDIATE RELEASE MEDNAX Announces Financial Leadership Transition C. Marc Richards Appo
FOR MORE INFORMATION: Senior Vice President, Finance and Strategy 954-384-0175 ext. 5692 charles_lynch@mednax.com MEDNAX Announces Financial Leadership Transition C. Marc Richards Appointed Executive Vice President, to Succeed Stephen D. Farber as Chief Financial Officer FO
Read more →-MD
Jul 30, 2020FOR MORE INFORMATION: Charles Lynch Senior Vice President, Finance and Strategy 954-384-0175, x 5692 charles_lynch@mednax.com FOR IMMEDIATE RELEASE MEDNAX Reports Second Quarter Results Results from Continuing Operations
FOR MORE INFORMATION: Senior Vice President, Finance and Strategy 954-384-0175, x 5692 charles_lynch@mednax.com MEDNAX Reports Second Quarter Results Results from Continuing Operations Reflect Significant Recovery in Second Half of Quarter Following Initial Disruption from C
Read more →-MD
Jul 13, 2020FOR MORE INFORMATION: Charles Lynch Senior Vice President, Finance and Strategy 954-384-0175 ext. 5692 charles_lynch@mednax.com FOR IMMEDIATE RELEASE MEDNAX Announces Leadership and Board Transitions Mark S. Ordan Appoin
FOR MORE INFORMATION: Senior Vice President, Finance and Strategy charles_lynch@mednax.com Announces Leadership and Board Transitions Mark S. Ordan Appointed Chief Executive Officer, Succeeding Company Founder Roger J. Guy P. Sansone Appointed Chair of Board of Directors S
Read more →-MD
Jun 5, 2020FOR MORE INFORMATION: Charles Lynch Vice President, Strategy and Investor Relations 954-384-0175 ext. 5692 charles_lynch@mednax.com FOR IMMEDIATE RELEASE MEDNAX Announces Significant Progress in Strategic Transformation
FOR MORE INFORMATION: Vice President, Strategy and Investor Relations 954-384-0175 ext. 5692 charles_lynch@mednax.com MEDNAX Announces Significant Progress in Strategic Transformation Company Intends to Return to Original Name, Pediatrix Medical Group; to Refocus as Dedicat
Read more →-MD
May 7, 2020FOR MORE INFORMATION: Charles Lynch Vice President, Strategy and Investor Relations 954-384-0175, x 5692 charles_lynch@mednax.com FOR IMMEDIATE RELEASE MEDNAX Reports First Quarter Results Completes Sale of American Anes
FOR MORE INFORMATION: Vice President, Strategy and Investor Relations 954-384-0175, x 5692 charles_lynch@mednax.com MEDNAX Reports First Quarter Results Completes Sale of American Anesthesiology to North American Partners in Anesthesia FORT LAUDERDALE, Fla., May 7, 2020 - M
Read more →-MD
May 6, 2020UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION Overview On
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION On May 6, 2020, MEDNAX, Inc., a Florida corporation (the Company ), through MEDNAX Services, Inc., a Florida corporation and wholly-owned subsidiary of the Company, entered into a Securities Purchase Agreement wit
Read more →-MD
May 6, 2020North American Partners in Anesthesia (NAPA) Acquires American Anesthesiology From MEDNAX, Inc., to Create One of the Most Comprehensive Anesthesia, Pain Management, and Perioperative Care Companies in the U.S. Melville,
North American Partners in Anesthesia (NAPA) Acquires American Anesthesiology From MEDNAX, Inc., to Create One of the Most Comprehensive Anesthesia, Pain Management, and Perioperative Care Companies in the U.S. Melville, NY and Fort Lauderdale, FL May 6, 2020 North American Pa
Read more →-MD
Mar 25, 2020FOR MORE INFORMATION: Charles Lynch Vice President, Strategy and Investor Relations 954-384-0175, x 5692 charles_lynch@mednax.com FOR IMMEDIATE RELEASE MEDNAX Provides COVID-19-Related Business Update Withdraws Prior Fir
FOR MORE INFORMATION: Vice President, Strategy and Investor Relations 954-384-0175, x 5692 charles_lynch@mednax.com MEDNAX Provides COVID-19-Related Business Update Withdraws Prior First-Quarter and Preliminary Full Year Outlook for 2020 Due to COVID-19 Impact Amends Credi
Read more →-MD
Feb 20, 2020FOR MORE INFORMATION: Charles Lynch Vice President, Strategy and Investor Relations 954-384-0175, x 5692 charles_lynch@mednax.com FOR IMMEDIATE RELEASE MEDNAX Reports Fourth Quarter Results Announces Multi-State, Unilate
FOR MORE INFORMATION: Vice President, Strategy and Investor Relations charles_lynch@mednax.com Fourth Quarter Results Announces Multi-State, Unilateral Termination by UnitedHealth Group FORT LAUDERDALE, Fla., February 20, 2020 - MEDNAX, Inc. (NYSE: MD), the national health
Read more →-MD
Nov 1, 2019FOR MORE INFORMATION: Charles Lynch Vice President, Strategy and Investor Relations 954-384-0175, x 5692 charles_lynch@mednax.com FOR IMMEDIATE RELEASE MEDNAX Reports Third Quarter Results Completes Sale of MedData Busin
FOR MORE INFORMATION: Vice President, Strategy and Investor Relations 954-384-0175, x 5692 charles_lynch@mednax.com MEDNAX Reports Third Quarter Results Completes Sale of MedData Business to Frazier Healthcare Partners FORT LAUDERDALE, Fla., November 1, 2019 - MEDNAX, Inc.
Read more →-MD
Oct 10, 2019FOR MORE INFORMATION: Charles Lynch Vice President, Strategy and Investor Relations 954-384-0175 ext. 5692 charles_lynch@mednax.com FOR IMMEDIATE RELEASE MEDNAX Reaches Agreement to Sell MedData Business to Frazier Healt
FOR MORE INFORMATION: Vice President, Strategy and Investor Relations 954-384-0175 ext. 5692 charles_lynch@mednax.com MEDNAX Reaches Agreement to Sell MedData Business to Frazier Healthcare Partners FORT LAUDERDALE, Fla., October 10, 2019 MEDNAX, Inc. (NYSE: MD) ( MEDNAX or
Read more →-MD
Aug 1, 2019FOR MORE INFORMATION: Charles Lynch Vice President, Strategy and Investor Relations 954-384-0175, x 5692 charles_lynch@mednax.com FOR IMMEDIATE RELEASE MEDNAX Reports Second Quarter GAAP EPS from Continuing Operations of
FOR MORE INFORMATION: Vice President, Strategy and Investor Relations 954-384-0175, x 5692 charles_lynch@mednax.com MEDNAX Reports Second Quarter GAAP EPS from Continuing Operations of $0.42; Adjusted EPS from Continuing Operations of $0.89 FORT LAUDERDALE, Fla., August 1,
Read more →-MD
May 2, 2019FOR MORE INFORMATION: Charles Lynch Vice President, Strategy and Investor Relations 954-384-0175, x 5692 charles_lynch@mednax.com FOR IMMEDIATE RELEASE MEDNAX Reports First Quarter GAAP EPS from Continuing Operations of
FOR MORE INFORMATION: Vice President, Strategy and Investor Relations 954-384-0175, x 5692 charles_lynch@mednax.com MEDNAX Reports First Quarter GAAP EPS from Continuing Operations of $0.48; Adjusted EPS from Continuing Operations of $0.65 Results Reflect Classification of
Read more →-MD
Mar 28, 2019FOR MORE INFORMATION: Charles Lynch Vice President, Strategy and Investor Relations 954-384-0175 ext. 5692 charles_lynch@mednax.com FOR IMMEDIATE RELEASE MEDNAX Announces Board of Directors Nominees Carlos A. Migoya and
FOR MORE INFORMATION: Vice President, Strategy and Investor Relations 954-384-0175 ext. 5692 charles_lynch@mednax.com MEDNAX Announces Board of Directors Nominees Carlos A. Migoya and Michael A. Rucker Nominated for Election to the Company s Board of Directors LAUDERDALE,
Read more →-MD
Feb 7, 2019FOR MORE INFORMATION: Charles Lynch Vice President, Strategy and Investor Relations 954-384-0175, x 5692 charles_lynch@mednax.com FOR IMMEDIATE RELEASE MEDNAX Reports Fourth Quarter GAAP EPS of $0.68; Adjusted EPS of $0.
FOR MORE INFORMATION: Vice President, Strategy and Investor Relations 954-384-0175, x 5692 charles_lynch@mednax.com MEDNAX Reports Fourth Quarter GAAP EPS of $0.68; Adjusted EPS of $0.92 Provides Guidance for First Quarter and Full Year 2019 FORT LAUDERDALE, Fla., February
Read more →-MD
Nov 1, 2018FOR MORE INFORMATION: Charles Lynch Vice President, Strategy and Investor Relations 954-384-0175, x 5692 charles_lynch@mednax.com FOR IMMEDIATE RELEASE MEDNAX Reports Third Quarter GAAP EPS of $0.72; Adjusted EPS of $0.9
FOR MORE INFORMATION: Vice President, Strategy and Investor Relations 954-384-0175, x 5692 charles_lynch@mednax.com MEDNAX Reports Third Quarter GAAP EPS of $0.72; Adjusted EPS of $0.94 Announces Initiation of Process to Sell MedData FORT LAUDERDALE, Fla., November 1, 2018
Read more →-MD
Sep 4, 2018FOR MORE INFORMATION: Charles Lynch Vice President, Strategy and Investor Relations 954-384-0175, x-5692 charles_lynch@mednax.com FOR IMMEDIATE RELEASE MEDNAX Commences $250 Million Accelerated Share Repurchase Program
FOR MORE INFORMATION: Vice President, Strategy and Investor Relations 954-384-0175, x-5692 charles_lynch@mednax.com MEDNAX Commences $250 Million Accelerated Share Repurchase Program FORT LAUDERDALE, Fla., September 4, 2018 MEDNAX, Inc. (NYSE: MD), the national medical group
Read more →-MD
Aug 2, 2018FOR MORE INFORMATION: Charles Lynch Vice President, Strategy and Investor Relations 954-384-0175, x 5692 charles_lynch@mednax.com FOR IMMEDIATE RELEASE MEDNAX Reports Second Quarter GAAP EPS of $0.85; Adjusted EPS of $1.
FOR MORE INFORMATION: Vice President, Strategy and Investor Relations 954-384-0175, x 5692 charles_lynch@mednax.com MEDNAX Reports Second Quarter GAAP EPS of $0.85; Adjusted EPS of $1.07 Expands Financial and Operational Improvement Targets Board Authorizes Share Repurchas
Read more →-MD
Apr 30, 2018FOR MORE INFORMATION: Charles Lynch Vice President, Strategy and Investor Relations 954-384-0175, x 5692 charles_lynch@mednax.com FOR IMMEDIATE RELEASE MEDNAX Reports First Quarter GAAP EPS of $0.68; Adjusted EPS of $0.8
FOR MORE INFORMATION: Vice President, Strategy and Investor Relations charles_lynch@mednax.com First Quarter GAAP EPS of $0.68; Adjusted EPS of $0.89 FORT LAUDERDALE, Fla., April 30, 2018 MEDNAX, Inc. (NYSE: MD), the national health solutions partner specializing in neonato
Read more →-MD
Feb 8, 2018FOR MORE INFORMATION: Charles Lynch Vice President, Strategy and Investor Relations 954-384-0175, x 5692 charles_lynch@mednax.com FOR IMMEDIATE RELEASE MEDNAX Reports Fourth Quarter GAAP EPS of $1.46; Adjusted EPS of $0.
FOR MORE INFORMATION: Vice President, Strategy and Investor Relations 954-384-0175, x 5692 charles_lynch@mednax.com MEDNAX Reports Fourth Quarter GAAP EPS of $1.46; Adjusted EPS of $0.87 Fla., February 8, 2018 MEDNAX, Inc. (NYSE: MD), the national health solutions partner s
Read more →-MD
Nov 1, 2017FOR MORE INFORMATION: Charles Lynch Vice President, Strategy and Investor Relations 954-384-0175, x 5692 charles_lynch@mednax.com FOR IMMEDIATE RELEASE MEDNAX Reports Third Quarter GAAP EPS of $0.71; Adjusted EPS of $0.8
FOR MORE INFORMATION: Vice President, Strategy and Investor Relations 954-384-0175, x 5692 charles_lynch@mednax.com MEDNAX Reports Third Quarter GAAP EPS of $0.71; Adjusted EPS of $0.87 Fla., November 1, 2017 - MEDNAX, Inc. (NYSE: MD), the national health solutions partner
Read more →-MD
Jul 28, 2017FOR MORE INFORMATION: Charles Lynch Vice President, Strategy and Investor Relations 954-384-0175, x 5692 charles_lynch@mednax.com FOR IMMEDIATE RELEASE MEDNAX Reports Second Quarter GAAP EPS of $0.69; Adjusted EPS of $0.
FOR MORE INFORMATION: Vice President, Strategy and Investor Relations 954-384-0175, x 5692 charles_lynch@mednax.com Second Quarter GAAP EPS of $0.69; Adjusted EPS of $0.85 FORT LAUDERDALE, Fla., July 28, 2017 MEDNAX, Inc. (NYSE: MD), the national health solutions partner sp
Read more →-MD
May 4, 2017FOR MORE INFORMATION: Charles Lynch Vice President, Strategy and Investor Relations 954-384-0175, x 5692 charles_lynch@mednax.com FOR IMMEDIATE RELEASE MEDNAX Reports First Quarter GAAP EPS of $0.59; Adjusted EPS of $0.7
FOR MORE INFORMATION: Vice President, Strategy and Investor Relations 954-384-0175, x 5692 charles_lynch@mednax.com First Quarter GAAP EPS of $0.59; Adjusted EPS of $0.75 FORT LAUDERDALE, Fla., May 4, 2017 - MEDNAX, Inc. (NYSE: MD), the national health solutions partner spe
Read more →-MD
Apr 20, 2017FOR MORE INFORMATION: Charles Lynch Vice President, Strategy and Investor Relations 954-384-0175, x 5692 charles_lynch@mednax.com FOR IMMEDIATE RELEASE MEDNAX Previews 2017 First Quarter Results FORT LAUDERDALE, Fla .
FOR MORE INFORMATION: Vice President, Strategy and Investor Relations 954-384-0175, x 5692 charles_lynch@mednax.com MEDNAX Previews 2017 First Quarter Results FORT LAUDERDALE, Fla., April 20, 2017 MEDNAX, Inc. (NYSE: MD), today announced preliminary financial and operating r
Read more →-MD
Feb 7, 2017FOR MORE INFORMATION: Charles Lynch Vice President, Strategy and Investor Relations 954-384-0175, x 5692 charles_lynch@mednax.com FOR IMMEDIATE RELEASE MEDNAX Reports Fourth Quarter GAAP EPS of $0.84; Adjusted EPS of $1.
FOR MORE INFORMATION: Vice President, Strategy and Investor Relations 954-384-0175, x 5692 charles_lynch@mednax.com Fourth Quarter GAAP EPS of $0.84; Adjusted EPS of $1.00 FORT LAUDERDALE, Fla., February 7, 2017 - MEDNAX, Inc. (NYSE: MD), the national health solutions partn
Read more →-MD
Nov 7, 2016FOR MORE INFORMATION: Charles Lynch Vice President, Strategy and Investor Relations 954-384-0175, x 5692 charles_lynch@mednax.com FOR IMMEDIATE RELEASE MEDNAX Announces Divisional Leadership Changes
FOR MORE INFORMATION: Vice President, Strategy and Investor Relations 954-384-0175, x 5692 charles_lynch@mednax.com Announces Divisional Leadership Changes FORT LAUDERDALE, Fla., November 7, 2016 MEDNAX, Inc. (NYSE: MD), today announced that Karl Wagner, President of the Co
Read more →-MD
Oct 27, 2016FOR MORE INFORMATION: Charles Lynch Vice President, Strategy and Investor Relations 954-384-0175, x 5692 charles_lynch@mednax.com FOR IMMEDIATE RELEASE MEDNAX Reports Third Quarter GAAP EPS of $1.04; Adjusted EPS of $1.0
FOR MORE INFORMATION: Vice President, Strategy and Investor Relations 954-384-0175, x 5692 charles_lynch@mednax.com Third Quarter GAAP EPS of $1.04; Adjusted EPS of $1.09 FORT LAUDERDALE, Fla., October 27, 2016 - MEDNAX, Inc. (NYSE: MD), the national medical group specializ
Read more →-MD
Jul 28, 2016FOR MORE INFORMATION: Charles Lynch Vice President, Strategy and Investor Relations 954-384-0175, x 5692 charles_lynch@mednax.com FOR IMMEDIATE RELEASE MEDNAX Reports Second Quarter GAAP EPS of $0.89; Adjusted EPS of $1.
FOR MORE INFORMATION: Vice President, Strategy and Investor Relations 954-384-0175, x 5692 charles_lynch@mednax.com Second Quarter GAAP EPS of $0.89; Adjusted EPS of $1.03 FORT LAUDERDALE, Fla., July 28, 2016 - MEDNAX, Inc. (NYSE: MD), the national medical group specializin
Read more →-MD
Apr 28, 2016FOR MORE INFORMATION: Charles Lynch Vice President, Strategy and Investor Relations 954-384-0175, x 5692 charles_lynch@mednax.com FOR IMMEDIATE RELEASE MEDNAX Reports First Quarter Adjusted EPS of $0.87; GAAP EPS of $0.7
FOR MORE INFORMATION: Vice President, Strategy and Investor Relations 954-384-0175, x 5692 charles_lynch@mednax.com First Quarter Adjusted EPS of $0.87; GAAP EPS of $0.73 Reports EBITDA Growth of 12 percent FORT LAUDERDALE, Fla., April 28, 2016 MEDNAX, Inc. (NYSE: MD), the
Read more →-MD
Feb 4, 2016FOR MORE INFORMATION: Charles Lynch Vice President, Strategy and Investor Relations 954-384-0175, x-5692 charles_lynch@mednax.com FOR IMMEDIATE RELEASE MEDNAX Reports Double-Digit Fourth Quarter 2015 Revenue and EPS Grow
FOR MORE INFORMATION: Vice President, Strategy and Investor Relations 954-384-0175, x-5692 charles_lynch@mednax.com MEDNAX Reports Double-Digit Fourth Quarter 2015 Revenue and EPS Growth Reports Fourth-Quarter Adjusted EPS of $1.13 Expects First Quarter 2016 Adjusted EPS of
Read more →-MD
Oct 29, 2015FOR MORE INFORMATION: Charles Lynch Vice President, Strategy and Investor Relations 954-384-0175, x-5692 charles_lynch@mednax.com FOR IMMEDIATE RELEASE MEDNAX Reports 2015 Third Quarter Adjusted EPS of $1.10 Expects Four
FOR MORE INFORMATION: Vice President, Strategy and Investor Relations 954-384-0175, x-5692 charles_lynch@mednax.com 2015 Third Quarter Adjusted EPS of $1.10 Expects Fourth Quarter Adjusted EPS of $1.10 to $1.14 FORT LAUDERDALE, Fla., October 29, 2015 MEDNAX, Inc. (NYSE: MD)
Read more →-MD
Jul 30, 2015FOR MORE INFORMATION: Charles Lynch Vice President, Strategy and Investor Relations 954-384-0175, x-5692 charles_lynch@mednax.com FOR IMMEDIATE RELEASE MEDNAX Reports 2015 Second Quarter EPS of $0.90 Introduces Use of EB
FOR MORE INFORMATION: Vice President, Strategy and Investor Relations 954-384-0175, x-5692 charles_lynch@mednax.com 2015 Second Quarter EPS of $0.90 Introduces Use of EBITDA and Adjusted EPS FORT LAUDERDALE, Fla., July 30, 2015 MEDNAX, Inc. (NYSE: MD), the national medical
Read more →-MD
May 18, 2015FOR MORE INFORMATION: Charles Lynch Vice President, Strategy and Investor Relations 954-384-0175, x-5692 charles_lynch@mednax.com FOR IMMEDIATE RELEASE MEDNAX Completes Acquisition of vRad Expects Initial Annualized Accr
FOR MORE INFORMATION: Vice President, Strategy and Investor Relations 954-384-0175, x-5692 charles_lynch@mednax.com Completes Acquisition of vRad Expects Initial Annualized Accretion of $0.10 per Share FORT LAUDERDALE, Fla., May 18, 2015 MEDNAX, Inc. (NYSE: MD), the nationa
Read more →-MD
Apr 30, 2015FOR MORE INFORMATION: Charles Lynch Vice President, Strategy and Investor Relations 954-384-0175, x-5692 charles_lynch@mednax.com FOR IMMEDIATE RELEASE MEDNAX Reports 2015 First Quarter EPS Growth of 14% to $0.72 Expects
FOR MORE INFORMATION: Vice President, Strategy and Investor Relations 954-384-0175, x-5692 charles_lynch@mednax.com 2015 First Quarter EPS Growth of 14% to $0.72 Expects Second Quarter EPS of $0.85 to $0.89 FORT LAUDERDALE, Fla., April 30, 2015 MEDNAX, Inc. (NYSE: MD), the
Read more →-MD
Mar 12, 2015FOR MORE INFORMATION: Charles Lynch Vice President, Strategy and Investor Relations 954-384-0175, x-5692 charles_lynch@mednax.com FOR IMMEDIATE RELEASE MEDNAX Commences Second $200 Million Accelerated Share Repurchase Pr
FOR MORE INFORMATION: Vice President, Strategy and Investor Relations 954-384-0175, x-5692 charles_lynch@mednax.com Commences Second $200 Million Accelerated Share Repurchase Program FORT LAUDERDALE, Fla., March 12, 2015 MEDNAX, Inc. (NYSE: MD), the national medical group s
Read more →-MD
Jan 29, 2015FOR MORE INFORMATION: Charles Lynch Vice President, Strategy and Investor Relations 954-384-0175, x-5692 charles_lynch@mednax.com FOR IMMEDIATE RELEASE MEDNAX Reports Double-Digit Fourth Quarter 2014 Revenue and EPS Grow
FOR MORE INFORMATION: Vice President, Strategy and Investor Relations 954-384-0175, x-5692 charles_lynch@mednax.com Double-Digit Fourth Quarter 2014 Revenue and EPS Growth Reports Fourth-Quarter EPS of $0.89 and Full-Year EPS of $3.18 Expects First Quarter 2015 EPS of $0.68
Read more →-MD
Dec 15, 2014FOR MORE INFORMATION: Charles Lynch Vice President, Strategy and Investor Relations 954-384-0175, x-5692 charles_lynch@mednax.com FOR IMMEDIATE RELEASE MEDNAX Commences $200 Million Accelerated Share Repurchase Program
FOR MORE INFORMATION: Vice President, Strategy and Investor Relations 954-384-0175, x-5692 charles_lynch@mednax.com MEDNAX Commences $200 Million Accelerated Share Repurchase Program FORT LAUDERDALE, Fla., December 15, 2014 MEDNAX, Inc. (NYSE: MD), the national medical group
Read more →-MD
Jul 31, 2014FOR MORE INFORMATION: Charles Lynch Vice President, Strategy and Investor Relations 954-384-0175, x-5692 charles_lynch@mednax.com FOR IMMEDIATE RELEASE MEDNAX Reports 2014 Second Quarter EPS of $0.79 Expects Third Quarte
FOR MORE INFORMATION: Vice President, Strategy and Investor Relations 954-384-0175, x-5692 charles_lynch@mednax.com 2014 Second Quarter EPS of $0.79 Expects Third Quarter EPS of $0.82 to $0.86 FORT LAUDERDALE, Fla., July 31, 2014 MEDNAX, Inc. (NYSE: MD), the national medica
Read more →-MD
May 1, 2014FOR MORE INFORMATION: Charles Lynch Vice President, Strategy and Investor Relations 954-384-0175, x-5692 charles_lynch@mednax.com FOR IMMEDIATE RELEASE MEDNAX Reports 2014 First Quarter EPS of $0.63 Expects Second Quarte
FOR MORE INFORMATION: Vice President, Strategy and Investor Relations 954-384-0175, x-5692 charles_lynch@mednax.com 2014 First Quarter EPS of $0.63 Expects Second Quarter EPS of $0.75 to $0.79 FORT LAUDERDALE, Fla., May 1, 2014 MEDNAX, Inc. (NYSE: MD), the national medical
Read more →-MD
Jan 30, 2014FOR MORE INFORMATION: Company Contact: Vivian Lopez-Blanco, 954-384-0175, x-5020 Chief Financial Officer/Treasurer vivian_lopezblanco@mednax.com Investor Relations Contact: Westwicke Partners Charles Lynch, 443-213-0504
FOR MORE INFORMATION: Vivian Lopez-Blanco, 954-384-0175, x-5020 vivian_lopezblanco@mednax.com Investor Relations Contact: Charles Lynch, 443-213-0504 charles.lynch@westwicke.com MEDNAX Earns $0.78 Per Share for 2013 Fourth Quarter 2013 Fourth Quarter Net Income Increases b
Read more →-MD
Jul 30, 2013MEDNAX Reports 2013 Second Quarter EPS of $1.37 Board Authorizes Share Repurchase Program FORT LAUDERDALE, Fla.--(BUSINESS WIRE)
Reports 2013 Second Quarter EPS of $1.37 Authorizes Share Repurchase Program FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--July 30, 2013--MEDNAX, Inc. (NYSE: MD), the national medical group specializing in neonatal, maternal-fetal, pediatric cardiology, other pediatric subspecialti
Read more →-MD
May 2, 2013MEDNAX Reports 2013 First Quarter EPS of $1.10 Expects Second Quarter 2013 EPS of $1.32 to $1.37 FORT LAUDERDALE, Fla.--(BUSINESS WIRE)
Reports 2013 First Quarter EPS of $1.10 Second Quarter 2013 EPS of $1.32 to $1.37 FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--May 2, 2013--MEDNAX, Inc. (NYSE: MD), the national medical group specializing in neonatal, maternal-fetal, pediatric cardiology, other pediatric subspecia
Read more →-MD
Jan 31, 2013MEDNAX Earns $1.32 Per Share for 2012 Fourth Quarter 2012 Net Income Increases by over 10% Expects First Quarter 2013 EPS of $1.05 to $1.10 FORT LAUDERDALE, Fla.--(BUSINESS WIRE)
Earns $1.32 Per Share for 2012 Fourth Quarter Net Income Increases by over 10% First Quarter 2013 EPS of $1.05 to $1.10 FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--January 31, 2013--MEDNAX, Inc. (NYSE: MD), the national medical group specializing in neonatal, maternal-fetal, ped
Read more →-MD
Nov 20, 2012FOR MORE INFORMATION: David T. Parker Vice President, Investor Relations & Corporate Communications MEDNAX, Inc. 954-384-0175, x 5300 david_parker@mednax.com FOR IMMEDIATE RELEASE MEDNAX Increases Credit Facility to $800
FOR MORE INFORMATION: Vice President, Investor Relations & Corporate Communications 954-384-0175, x 5300 david_parker@mednax.com MEDNAX Increases Credit Facility to $800 Million to Fund Future Growth; Facility May be Further Expanded to $1 Billion FORT LAUDERDALE, Fla., Nov
Read more →-MD
Nov 1, 2012MEDNAX Earns $1.32 Per Share for 2012 Third Quarter Exceeds Third Quarter Earnings Guidance Expects Fourth Quarter EPS of $1.27 to $1.32 FORT LAUDERDALE, Fla.--(BUSINESS WIRE)
Earns $1.32 Per Share for 2012 Third Quarter Third Quarter Earnings Guidance Fourth Quarter EPS of $1.27 to $1.32 FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--November 1, 2012--MEDNAX, Inc. (NYSE: MD), the national medical group specializing in neonatal, maternal-fetal, pediatric
Read more →-MD
Jul 31, 2012MEDNAX Exceeds Second Quarter Earnings Guidance, Earns $1.22 Per Share for 2012 Second Quarter Expects Third Quarter EPS of $1.25 to $1.30 FORT LAUDERDALE, Fla.--(BUSINESS WIRE)
Exceeds Second Quarter Earnings Guidance, Earns $1.22 Per Share for 2012 Third Quarter EPS of $1.25 to $1.30 FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--July 31, 2012--MEDNAX, Inc. (NYSE:MD), the national medical group specializing in neonatal, maternal-fetal, pediatric cardiolog
Read more →-MD
May 3, 2012MEDNAX Reports 2012 First Quarter EPS of 98 Cents FORT LAUDERDALE, Fla.--(BUSINESS WIRE)
Reports 2012 First Quarter EPS of 98 Cents FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--May 3, 2012--MEDNAX, Inc. (NYSE: MD), the national medical group specializing in neonatal, maternal-fetal, pediatric cardiology, other pediatric subspecialties and anesthesia physician services
Read more →-MD
Feb 2, 2012MEDNAX Earns $1.19 Per Share for 2011 Fourth Quarter 2011 Net Income Increases by over 13% (non-GAAP) FORT LAUDERDALE, Fla.--(BUSINESS WIRE)
Earns $1.19 Per Share for 2011 Fourth Quarter Net Income Increases by over 13% (non-GAAP) FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--February 2, 2012--MEDNAX, Inc. (NYSE: MD), the national medical group specializing in neonatal, maternal-fetal, pediatric cardiology, other pediat
Read more →-MD
Nov 1, 2011MEDNAX Earns $1.19 Per Share for 2011 Third Quarter Expects Fourth Quarter EPS of $1.15 to $1.20 FORT LAUDERDALE, Fla.--(BUSINESS WIRE)
Earns $1.19 Per Share for 2011 Third Quarter Fourth Quarter EPS of $1.15 to $1.20 FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--November 1, 2011--MEDNAX, Inc. (NYSE: MD), the national medical group specializing in neonatal, maternal-fetal, pediatric cardiology, other pediatric subs
Read more →-MD
Oct 24, 2011FOR MORE INFORMATION: David T. Parker Vice President, Investor Relations & Corporate Communications 954-384-0175, x-5300 david_parker@mednax.com FOR IMMEDIATE RELEASE MEDNAX Expands Credit Facility to $500 Million and Ex
FOR MORE INFORMATION: Vice President, Investor Relations & Corporate Communications 954-384-0175, x-5300 david_parker@mednax.com MEDNAX Expands Credit Facility to $500 Million and Extends Through 2016 FORT LAUDERDALE, FL, October 24, 2011 MEDNAX, Inc. (NYSE: MD), the nationa
Read more →-MD
Aug 2, 2011MEDNAX Earns $1.15 Per Share for 2011 Second Quarter Expects Third Quarter EPS of $1.15 to $1.20 FORT LAUDERDALE, Fla.--(BUSINESS WIRE)
Earns $1.15 Per Share for 2011 Second Quarter Third Quarter EPS of $1.15 to $1.20 FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--August 2, 2011--MEDNAX, Inc. (NYSE: MD), the national medical group specializing in neonatal, maternal-fetal, pediatric cardiology, other pediatric subspe
Read more →-MD
May 3, 2011MEDNAX's 2011 First Quarter EPS Grows by 16 Percent to 94 Cents Expects Second Quarter EPS of $1.11 to $1.17 FORT LAUDERDALE, Fla.--(BUSINESS WIRE)
2011 First Quarter EPS Grows by 16 Percent to 94 Cents Second Quarter EPS of $1.11 to $1.17 FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--May 3, 2011--MEDNAX, Inc. (NYSE: MD) today reported earnings per share of 94 cents for the three months ended March 31, 2011, that were driven b
Read more →-MD
Feb 3, 2011MEDNAX Earns $1.12 Per Share for 2010 Fourth Quarter Expects 2011 First Quarter EPS Growth of 9 to 15 Percent FORT LAUDERDALE, Fla.--(BUSINESS WIRE)
Earns $1.12 Per Share for 2010 Fourth Quarter 2011 First Quarter EPS Growth of 9 to 15 Percent FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--February 3, 2011--MEDNAX, Inc. (NYSE: MD), the national medical group specializing in neonatal, maternal-fetal, pediatric cardiology, other p
Read more →-MD
Nov 2, 2010MEDNAX Earns $1.06 Non-GAAP for 2010 Third Quarter Expects Fourth Quarter EPS of $1.10 to $1.14 FORT LAUDERDALE, Fla.--(BUSINESS WIRE)
Earns $1.06 Non-GAAP for 2010 Third Quarter Fourth Quarter EPS of $1.10 to $1.14 FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--November 2, 2010--MEDNAX, Inc. (NYSE: MD) today reported GAAP earnings per share of $1.29 for the three months ended September 30, 2010, or $1.06 per share
Read more →-MD
Aug 3, 2010MEDNAX Earns $1.04 Per Share in 2010 Second Quarter Generates $91.7 Million of Cash Flow from Operations FORT LAUDERDALE, Fla.--(BUSINESS WIRE)
Earns $1.04 Per Share in 2010 Second Quarter $91.7 Million of Cash Flow from Operations FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--August 3, 2010--MEDNAX, Inc. (NYSE: MD) today reported earnings per share of $1.04 for the three months ended June 30, 2010, that were driven by con
Read more →-MD
May 3, 2010MEDNAX Reports 2010 First Quarter Non-GAAP EPS of 82 Cents Expects Second Quarter EPS of $1.00 to $1.05 FORT LAUDERDALE, Fla.--(BUSINESS WIRE)
Reports 2010 First Quarter Non-GAAP EPS of 82 Cents Second Quarter EPS of $1.00 to $1.05 FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--May 3, 2010--MEDNAX, Inc. (NYSE: MD) today reported non-GAAP earnings of 82 cents per share for the 2010 first quarter that was principally the res
Read more →-MD
Feb 5, 2010MEDNAX Reports GAAP EPS of $1.07 for 2009 Fourth Quarter FORT LAUDERDALE, Fla.--(BUSINESS WIRE)
Reports GAAP EPS of $1.07 for 2009 Fourth Quarter FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--February 5, 2010--MEDNAX, Inc. (NYSE: MD), the national medical group providing hospital-based neonatal, anesthesia and pediatric physician services and office-based maternal-fetal and p
Read more →-MD
Nov 2, 2009MEDNAX Reports 2009 Third Quarter EPS of $1.03 FORT LAUDERDALE, Fla.--(BUSINESS WIRE)
Reports 2009 Third Quarter EPS of $1.03 FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--November 2, 2009--MEDNAX, Inc. (NYSE:MD) today reported record results from operations for the three months and nine months ended September 30, 2009, that reflect contributions from acquisitions,
Read more →-MD
Aug 4, 2009MEDNAX Earns 93 Cents Per Share in 2009 Second Quarter Expects Third Quarter EPS of 94 Cents to $1.00 FORT LAUDERDALE, Fla.--(BUSINESS WIRE)
Earns 93 Cents Per Share in 2009 Second Quarter Third Quarter EPS of 94 Cents to $1.00 FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--August 4, 2009--MEDNAX, Inc. (NYSE:MD) today reported earnings per share of 93 cents for the 2009 second quarter as a result of strong revenue growth
Read more →-MD
May 7, 2009MEDNAX Reports 2009 First Quarter EPS of 74 Cents Expects Second Quarter EPS of 84 to 90 Cents Per Share FORT LAUDERDALE, Fla.--(BUSINESS WIRE)
Reports 2009 First Quarter EPS of 74 Cents Second Quarter EPS of 84 to 90 Cents Per Share FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--May 7, 2009--MEDNAX, Inc. (NYSE:MD) today reported earnings of 74 cents per share for the 2009 first quarter that was the result of strong revenue
Read more →Competitive Position
How MD ranks across every disease it competes inCompetitive Position is a premium feature
See how MD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial